Edwards Lifesciences Co. (NYSE:EW) Director Steven R. Loranger Sells 5,739 Shares

Edwards Lifesciences Co. (NYSE:EW) Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Edwards Lifesciences Price Performance

NYSE:EW opened at $76.23 on Friday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The firm has a market cap of $44.96 billion, a price-to-earnings ratio of 11.00, a P/E/G ratio of 3.64 and a beta of 1.10. The firm’s 50-day simple moving average is $72.58 and its 200 day simple moving average is $69.41. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after buying an additional 6,537,494 shares during the period. Wellington Management Group LLP increased its holdings in Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock valued at $2,458,601,000 after buying an additional 1,678,154 shares during the period. State Street Corp increased its holdings in Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after buying an additional 256,538 shares during the period. Geode Capital Management LLC boosted its stake in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock valued at $1,007,520,000 after purchasing an additional 126,194 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after purchasing an additional 696,965 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday. Piper Sandler increased their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.